As for CTLA-4, previous studies have indicated that combining anti-CTLA-4 with anti-PD-1/PD-L1 may be a viable second-line therapy for BC (Kern & Panis, 2021; Sun et al., 2020). This evidence concerns the gene CTLA4 and breast cancer.